iSpot Lyme Test: “a Game-Changer”
A new test that measures T-cell response to antigens from Borrelia bergdorferi has the potential to vastly improve Lyme disease diagnosis—especially in the early phases.
The test, called iSpot Lyme, utilizes the Elispot technology introduced several years ago for evaluation of persistent tuberculosis.
The iSpot Lyme test is far more sensitive and specific than the standard Western Blot, which despite it’s limitations, remains a cornerstone of the CDC’s recommended diagnostic work-up. Physicians using the new test, developed by Pharmasan Labs and introduced earlier this year by NeuroScience Inc, are calling it a game-changer.